GPN Vaccines Awarded $936,000 CUREator Program Funding

GPN Vaccines Awarded $936,000 CUREator Program Funding


Adelaide, Australia – 7th May 2024 

GPN Vaccines Ltd is pleased to announce the successful award of $936,000 in Round 3 of Brandon BioCatalyst’s CUREator Program. This funding marks an important milestone in the Company’s journey toward advancing its novel pneumococcal vaccine, Gamma-PN.

Funding from the CUREator Program, which is supporting the development of preclinical and clinical innovations in Australia, will be used to gain further insights into the Company’s first-in-human study by understanding the duration of the immune response up to one year after dosing. This data is expected to add significant commercial value to the company.  

Dr Tim Hirst, GPN Vaccines’ Chief Executive Officer, said “The CUREator grant comes at a pivotal moment for GPN Vaccines as we progress from being a Phase 1 to a Phase 2 company. Being able to conduct a study on the durability of the immune response will strengthen  the valuation proposition of our pneumococcal vaccine and assist us as we seek to secure future investment.’

GPN Vaccines is globally recognised for its novel approach to bacterial vaccines, using gamma irradiation to create safe and highly immunogenic vaccines. The company’s portfolio encompasses a range of vaccine candidates targeting infectious bacteria, with the potential to revolutionise disease prevention strategies.

Professor Paul Rolan, Chief Medical Officer at GPN Vaccines, expressed the significance of securing this funding, stating “This funding will help us to expedite the development of Gamma-PN, with the ultimate aim of safeguarding communities worldwide against infectious diseases.”

Eight biotech projects have been funded by CUREator in Round 3 across the country in both the Preclinical and Clinical funding streams.


About GPN Vaccines

GPN Vaccines is a public (unlisted) clinical stage biotechnology company developing a vaccine against Streptococcus pneumoniae, which is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now more than 100 different serotypes of S. pneumoniae and the best vaccine currently on the market only protects against 20 of them. GPN Vaccines’ product, called Gamma-PN, is being developed to protect children and adults against all S. pneumoniae strains, regardless of serotype.

About CUREator

CUREator is a national biotechnology incubator by Brandon BioCatalyst to support the development of Australian biomedical research and innovations. Funded by the Medical Research Future Fund and Australia’s national science agency, CSIRO, CUREator provides grant funding programs for opportunities spanning from discovery to clinical development. Funding is provided like an investor with clear milestone-driven tranches to achieve key value-adding and de-risking development milestones. CUREator works closely with project teams to guide them through the early development phase, offering scientific and commercial expertise and networks to support projects meeting key outcomes.

For more information about CUREator, visit:

About Brandon BioCatalyst and Brandon Capital

Brandon Capital is Australasia’s leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK. From early-stage seed investment to expansion capital, and Brandon Capital supports life science companies from proof-of-concept to commercialisation.  Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of over 50 leading medical research institutes, investors, and government united by a single purpose: progressing the next generation of medical therapies and technology that improve health and save lives. |


Media contacts

Dr Tim Hirst

Chief Executive Officer

+61 420 942 824



Protecting children and adults from the world’s foremost bacterial pathogen